Authors
Loading...
Randomized trial evaluates probucol's anticancer effects in colorectal cancer cells, suggesting its potential as a multitarget therapeutic agent.
Kaya‐Sezginer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: